Phosphorylcholine monoclonal antibody - Athera Biotechnologies

Drug Profile

Phosphorylcholine monoclonal antibody - Athera Biotechnologies

Alternative Names: Fully human monoclonal antibody PC-mAb for cardiovascular disease (CVD) - Athera Biotechnologies; Fully human monoclonal IgG phosphorylcholine antibody - Athera Biotechnologies; Monoclonal antibody for atherosclerosis - Athera Biotechnologies; PC-mAb

Latest Information Update: 11 Jul 2016

Price : $50

At a glance

  • Originator Dyax
  • Developer Athera Biotechnologies
  • Class Cardiovascular therapies; Monoclonal antibodies
  • Mechanism of Action LDL receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase I Cardiovascular disorders
  • Preclinical Atherosclerosis; Coronary artery restenosis

Most Recent Events

  • 11 Jul 2016 Phase I development is ongoing in Sweden
  • 22 Jan 2016 Dyax has been acquired by and merged into Shire
  • 01 May 2015 Athera Biotechnologies in-licenses phosphorylcholine monoclonal antibody from Dyax before May 2015 (Dyax 10-K, May 2015)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top